GLP1R and Parkinson disease: Since GLP-1 signaling activates AKT, one plausible explanation for its therapeutic effect in PD to reduce glial inflammation is through this increased activity in order to elevate levels of the Inhibitor of NF-κB (IκBα), ultimately leading to a reduction in neuroinflammation (26, 301).